ANI Pharmaceuticals Inc. (ANIP)

68.47
NASDAQ : Health Technology
Prev Close 68.43
Day Low/High 67.83 / 69.51
52 Wk Low/High 36.92 / 74.00
Avg Volume 103.00K
Exchange NASDAQ
Shares Outstanding 12.04M
Market Cap 824.44M
EPS 1.30
P/E Ratio 58.99
Div & Yield N.A. (N.A)

Latest News

ANI Pharmaceuticals Schedules Conference Call To Discuss First Quarter 2019 Financial Results

ANI Pharmaceuticals Schedules Conference Call To Discuss First Quarter 2019 Financial Results

BAUDETTE, Minn., May 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Expands Injectable Portfolio With Distribution Agreement For FDA Approved Injectable Product

ANI Pharmaceuticals Expands Injectable Portfolio With Distribution Agreement For FDA Approved Injectable Product

BAUDETTE, Minn., April 15, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Reaches Analyst Target Price

ANI Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of ANI Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $70.33, changing hands for $70.54/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

ANI Pharmaceuticals Announces Two Generic Product Launches

ANI Pharmaceuticals Announces Two Generic Product Launches

BAUDETTE, Minn., March 27, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANIP, FTAI, LGCY, SSB, TERP, YPF Downgrades: ABC, GLOG, ICUI, NWS, SQM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

ANI Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For ANIP

ANI Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For ANIP

In trading on Tuesday, shares of ANI Pharmaceuticals Inc crossed above their 200 day moving average of $57.89, changing hands as high as $58.04 per share. ANI Pharmaceuticals Inc shares are currently trading up about 3% on the day.

Even Wall Street Experts Had a Tough Year in 2018

Even Wall Street Experts Had a Tough Year in 2018

Barron's big-name money managers did not pick many winners for the year.

Even the Experts Had a Tough Year in 2018

Even the Experts Had a Tough Year in 2018

Barron's big-name money managers did not pick many winners for the year.

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Notable Two Hundred Day Moving Average Cross - ANIP

Notable Two Hundred Day Moving Average Cross - ANIP

In trading on Tuesday, shares of ANI Pharmaceuticals Inc crossed below their 200 day moving average of $64.00, changing hands as low as $49.76 per share. ANI Pharmaceuticals Inc shares are currently trading off about 12.9% on the day.

Small-Caps Offer Port in Stormy Trade Seas

Small-Caps Offer Port in Stormy Trade Seas

Small-caps also should benefit from reduced corporate income taxes and strong U.S. economic growth.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

3 Biotech Stocks I Love for March (Celgene Is One of Them)

3 Biotech Stocks I Love for March (Celgene Is One of Them)

These biotech names are all great buys on dips. Notably Celgene, which is fresh off a terrible trading session.

3 Promising Biotech Stocks to Buy on Dips

3 Promising Biotech Stocks to Buy on Dips

From ANI Pharmaceuticals to T2 Biosystems, these names look good.

Three Biotech Opportunities

Three Biotech Opportunities

Celgene, ANI and T2 are seeing attractive entry points.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CXO, GOGL, LBRDA, LBRDK Downgrades: ANIP, CTB, HVT, HVT.A, MANH, MDT, MSA, PMBC, TAYD, TGH, UBP Initiations: CJ, FTI, VREX Read on to get TheStreet Quant Ratings' detailed report:

Commit To Purchase ANI Pharmaceuticals At $35, Earn 18.7% Annualized Using Options

Commit To Purchase ANI Pharmaceuticals At $35, Earn 18.7% Annualized Using Options

Investors eyeing a purchase of ANI Pharmaceuticals Inc shares, but tentative about paying the going market price of $60.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March put at the $35 strike, which has a bid at the time of this writing of 70 cents.

ANI Pharmaceuticals Reaches Analyst Target Price

ANI Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of ANI Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $66.33, changing hands for $68.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

ANIP Crosses Above Average Analyst Target

ANIP Crosses Above Average Analyst Target

In recent trading, shares of ANI Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $66.33, changing hands for $74.56/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AINV, AMOT, ANIP, EXFO, EXPR, INBK, LIND, LNN, LTM, MJCO, MYRG, SGEN, WEYS Downgrades: BAM, ESRT, IAG, PGRE, RRTS, SSRM Initiations: RARE Read on to get TheStreet Quant Ratings' detailed report:

3 Small-Caps on My Growth Stock Radar

3 Small-Caps on My Growth Stock Radar

LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.

ANI Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ANIP

ANI Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ANIP

In trading on Wednesday, shares of ANI Pharmaceuticals Inc crossed above their 200 day moving average of $51.40, changing hands as high as $51.80 per share. ANI Pharmaceuticals Inc shares are currently trading up about 3.3% on the day.

Commit To Buy ANI Pharmaceuticals At $30, Earn 10.1% Annualized Using Options

Commit To Buy ANI Pharmaceuticals At $30, Earn 10.1% Annualized Using Options

Investors considering a purchase of ANI Pharmaceuticals Inc stock, but cautious about paying the going market price of $50.73/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $30 strike, which has a bid at the time of this writing of $1.00.

TheStreet Quant Rating: B- (Buy)